Evolent Health, Inc. (NYSE:EVH) Shares Sold by AtonRa Partners

AtonRa Partners reduced its holdings in shares of Evolent Health, Inc. (NYSE:EVH) by 8.4% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 15,301 shares of the technology company’s stock after selling 1,404 shares during the quarter. AtonRa Partners’ holdings in Evolent Health were worth $505,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also made changes to their positions in the business. Gamco Investors INC. ET AL boosted its position in shares of Evolent Health by 0.5% in the 3rd quarter. Gamco Investors INC. ET AL now owns 97,000 shares of the technology company’s stock valued at $2,641,000 after purchasing an additional 500 shares during the period. New York State Common Retirement Fund boosted its position in shares of Evolent Health by 0.5% in the 3rd quarter. New York State Common Retirement Fund now owns 94,908 shares of the technology company’s stock valued at $2,584,000 after purchasing an additional 506 shares during the period. Teacher Retirement System of Texas boosted its position in shares of Evolent Health by 9.0% in the 3rd quarter. Teacher Retirement System of Texas now owns 8,293 shares of the technology company’s stock valued at $226,000 after purchasing an additional 685 shares during the period. Genesee Capital Advisors LLC boosted its position in shares of Evolent Health by 2.2% in the 4th quarter. Genesee Capital Advisors LLC now owns 38,390 shares of the technology company’s stock valued at $1,268,000 after purchasing an additional 825 shares during the period. Finally, Signaturefd LLC boosted its position in shares of Evolent Health by 1,470.7% in the 4th quarter. Signaturefd LLC now owns 1,445 shares of the technology company’s stock valued at $48,000 after purchasing an additional 1,353 shares during the period.

Wall Street Analysts Forecast Growth

EVH has been the subject of a number of research analyst reports. JMP Securities upped their target price on Evolent Health from $37.00 to $38.00 and gave the company a “market outperform” rating in a research report on Friday, February 23rd. JPMorgan Chase & Co. reduced their price objective on Evolent Health from $53.00 to $52.00 and set an “overweight” rating for the company in a research note on Friday, March 15th. William Blair reaffirmed an “outperform” rating on shares of Evolent Health in a research note on Tuesday, January 9th. Citigroup assumed coverage on Evolent Health in a research note on Monday, April 22nd. They set a “buy” rating and a $40.00 price objective for the company. Finally, Canaccord Genuity Group reduced their price objective on Evolent Health from $45.00 to $44.00 and set a “buy” rating for the company in a research note on Thursday, March 28th. One analyst has rated the stock with a sell rating, one has issued a hold rating and eleven have given a buy rating to the company’s stock. According to MarketBeat.com, Evolent Health presently has a consensus rating of “Moderate Buy” and an average price target of $42.70.

Evolent Health Stock Performance

Shares of EVH stock traded up $0.17 during trading hours on Monday, reaching $27.82. 640,331 shares of the company’s stock were exchanged, compared to its average volume of 943,359. The company has a market cap of $3.21 billion, a P/E ratio of -21.91 and a beta of 1.54. The company’s 50 day moving average is $31.71 and its two-hundred day moving average is $30.29. Evolent Health, Inc. has a 1 year low of $23.33 and a 1 year high of $36.70. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.01 and a quick ratio of 1.01.

Evolent Health (NYSE:EVH) last issued its earnings results on Thursday, February 22nd. The technology company reported $0.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.02 by $0.13. The business had revenue of $556.06 million during the quarter, compared to the consensus estimate of $541.87 million. Evolent Health had a positive return on equity of 6.60% and a negative net margin of 5.76%. Equities research analysts anticipate that Evolent Health, Inc. will post 0.87 EPS for the current fiscal year.

Evolent Health Company Profile

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.